Could a common mineral boost antidepressants? new trial investigates

NCT ID NCT07458022

Ongoing Symptom relief Sponsor: University of Child Health Sciences and Children's Hospital, Lahore Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding magnesium to a standard SSRI antidepressant works better than the SSRI alone for adults with major depressive disorder. Fifty participants will be randomly assigned to receive either the combination or just the SSRI. The main goal is to see if depression scores improve more with the added magnesium after 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: magnesium
What this could lead to: If it works, this could point toward a simple, low-cost way to boost the effectiveness of standard antidepressants for people with major depression.
What could go wrong: This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. It's also not yet clear if adding magnesium is safe or effective long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DIORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DIORDER

Contacts and locations

Locations

Combined Military Hospital (CMH)

Multan, Punjab Province, 60000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.